# III. Results

Comparison of mean NT-proBNP: IV. Discussion

? Among 30 controls: 1. 29 had NT-proBNP levels within normal range for their age. 2. 1 had elevated level of NT-ProBNP for their age.

? Among 30 cases: 3. 24 had NT-ProBNP level elevated for their age and were diagnosed to have congestive cardiac failure. 4. 6 had NT-ProBNP levels within normal limits for their age. These 6 patients had a normal 2D-ECHO. Breathlessness in these patients was due to non cardiac cause.   


# ETIOLOGY OF AMONG 30 CASES

ETIOLOGY OF DYSPNEA AMONG 30 CASES
![Heart failure prevalence is raising throughout the world. ? The overall prevalence of HF is thought to be increasing because current therapies for cardiac disorders, such as Myocardial Infarction (MI), Valvular Heart Disease, and Arrhythmias, are allowing patients to survive longer. ? American Heart Association (AHA) guidelines define HF as a "Complex clinical syndrome that results from structural or functional impairment of ventricular filling or ejection of blood, which in turn leads to the cardinal clinical symptoms of dyspnea and fatigue and signs of HF namely edema and rales". ? Making the correct diagnosis in patients with Suspected Acute Heart Failure is challenging, and confirmatory in only 40-50% of Cases. ? Several Studies have shown that when added to routine history, Clinical Examination and Conventional investigations measurement of plasma natriuretic peptide levels improve diagnostic accuracy. ? B-type natriuretic peptides (BNP) that are synthesized by the left and right atria in response to cardiomyocyte stretching. ? The human BNP gene encodes a 108 amino acid pro hormone named proBNP. ? ProBNP is cleaved in to a biologically active 32amino acid C-Terminal polypeptide (BNP) and a 76amino acid N-terminal fragment termed NT-proBNP. ? Both these polypeptides are released in to the circulation and can be detected in blood samples. II. Materials and Methods ? The study was conducted on 60 patients between the age group of 40-70 years attending the inpatient and outpatient clinic at Kempegowda Institute of Medical Sciences, Bangalore. ? It was a case control comparative study of 60 patients (30 cases and 30 controls) during the study period from November 2013 to October 2015. ? Informed consent was obtained from all patients /care takers of the patients enrolled for the study. ? The data of the patients was collected in a well designed platform. ? Relevant data about diabetes mellitus, hypertension and Renal disease was taken in the history.](image-2.png "?")
![NT-proBNp values by Ef values among the study groupsComparision of Mean NT-proBNp values by Ef values among the study groupsComparison of NT-proBNP levels with NYHA grading:Comparison of EF Values:](image-3.png "")
![](image-4.png "")
2. b) Exclusion Criteria1. Cor pulmonale.? CASES: Patients suspected to have heart failure based on history, Clinical examination and ECG (Age and Sex Matched individuals).2. Sepsis. 3. Lung Cancer. 4. Pulmonary Embolism. 5. ARDS.? CONTROLS: Patients without heart failure and6. Liver Cirrhosis.diseases mentioned in Exclusion Criteria.7. Renal failure.? In our study cutoff levels for NT-pro BNP was8. Patients not willing to participate in the study.1. >450 pg/ml for those aged < 50 years.2. >900 pg/ml for those aged 50-70 years.a) Inclusion Criteria1. Age 40-70 years.
Comparision of Mean EFvaaluesV. Discussion? The mean value of NT-proBNP raises with100.00% decreasing EF. NT-ProBNP values have a inverse100.00% relationship with Ef Values. There was a strongcorrelation between the 2 variable with a p value of 90.00% <0.001 80.00% ? There is a raise in NT-proBNP value with increasing70.00% NYHA grades. There was a significant correlation40.00% 50.00% between the 2 variables with a 'P' value of 0.049 60.00% ? The mean NT-ProBNP Value among controls was 568.43 pg/ml. The mean NT-proBNP value among cases as 8253.13pg/ml. It was statistically43.30%Normal DCm30.00% significant with a 'P' value of <0.001.IHD20.00% VI. Conclusion20.00%23.30%RHD0.00% 10.00%0.00% 0.00% 0.00%13.30%Control(N30)Case(N30)1
			NT-proBNP as a Diagnostic Marker in CCF © 2016 Global Journals Inc. (US)
		
		
			

				


* 
	
		Prevention of heart failure: A scientific statement from the American heart association councils on Epidemiology and prevention
		
			DDSchocken
		
		
			EJBenjamin
		
		
			GCFonarrow
		
	
	
		Cardiovascular Nursing, and high blood pressure Research; Quality care and Outcomes Research Interdisciplinary Working group; and Functional Genomics and Translational Biology Interdisciplinary Working Group
				
			2008
			117
			2544
		
	
	Circulation




* 
	
		Heart Failure : Pathophysiology and diagnosis
		
			D LMann
		
		
			MChakinala
		
	
	
		Harrison's Principles of internal Medicine 19 th ed
				McGraw-Hill
		
	




* 
	
		
		
			DLLongo
		
		
			ASFauci
		
		
			DLKasper
		
		
			SLHauser
		
		
			JLJameson
		
	
	
		Loscalzo J eds
		
			2
			2112
		
	




* 
	
		ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation
		
			CWYancy
		
		
			MJessup
		
		
			BBozkurt
		
		
			CaseyButlerj
		
		
			De
		
		
			MDrazner
		
	
	
		American Heart Association Task Forcw on Practice guidelines circulation
		
			128
			
			2013
		
	




* 
	
		ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC
		
			JjvMcmurray
		
		
			SAdamopoulos
		
		
			SDAnker
		
		
			AAuricchio
		
		
			MBohm
		
		
			KDickstein
		
	
	
		Eur J Heart Fail
		
			14
			
			2012
		
	




* 
	
		Combining tissue Doppler Echocardiography and B-type natriuretic peptide in the evaluation of left ventricular filling pressures: review of literature and clinical recommendations
		
			HDokainish
		
	
	
		Can J Cardiol
		
			23
			
			2007